Tatva Chintan Pharma Ltd IPO all set to make a debut in the stock market with an issue size of 500 Cr and is one of the leading chemical manufacturing company that manufactures structure directing agents.
Tatva Chintan Pharma LTD IPO -Overview
| Tatva Chintan Pharma Chem Limited IPO Issue Date | 16-20 July 2021 |
| Tatva Chintan Pharma Chem Limited IPO Opening Date | 29 July 2021 |
| Tatva Chintan Pharma Chem Limited IPO Face Value | INR 10 per share |
| Tatva Chintan Pharma Chem Limited IPO Price | INR 1083 per share |
| Tatva Chintan Pharma Chem Limited IPO Lot Size | 13 Shares |
| Issue Size | 500 Cr |
| Offer for sale | 275 Cr |
| Issue Type | Book built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | 185.23 times |
| NII (HNI) Shares | 512.22 times |
| Company Promoters | Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Snehkar Rasiklal Somani are the company promoters. |
Tatva Chintan Pharma LTD IPO-Tentative Dates
| Tatva Chintan Pharma Chem Limited IPO opening date | 16 July 2021 |
| Tatva Chintan Pharma Chem Limited IPO closing date | 20 July 2021 |
| Basis of Allotment | 26 July 2021 |
| Initiation of Refunds | 27 July 2021 |
| The credit of Shares to Demat | 28 July 2021 |
| Tatva Chintan Pharma Chem Limited IPO Listing Date | 29 July 2021 |
Tatva Chintan Pharma Chem – Industry Overview.
India’s Battery Electrolyte market stands at USD 0.35-0.4 Bn in 2019 projected to grow at 8-9% CAGR over the next half-decade to reach USD 0.55-0.65 Bn by the year 2024F. India’s battery electrolyte market is approximately 6-8% of the global battery electrolyte market. Automotive and Consumer Electronics comprise more than half of India’s market. The Automotive segment saw a drop in sales in the last 2 years; it is, however, expected to bounce back and grow exponentially. The demand for Hybrid vehicles and Electric Vehicles will in turn boost the demand from the Automotive and Transport industry. With a growing technologically savvy population and better standards of living, the demand for consumer electronics in the forms of Phones, Mobiles, Laptops, Music Players, Audio Assistants, and Reading Tablets among others is driving the Consumer Electronics market.
Tatva Chintan Pharma LTD IPO – Company Overview
Tatva Chintan Pharma is specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for supercapacitor batteries and pharmaceutical and agrochemical intermediates, and other specialty chemicals(“PASC”). The Company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second-largest position globally. In addition, the Company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, they focus on the application of the products which form a key ingredient in the customers’ manufacturing and industrial processes. For instance, the SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.
Tatva Chintan Pharma LTD IPO-Objectives
- Funding capital expenditures requirements for expansion of Dahej manufacturing facility.
- Funding capital expenditures requirements to upgrade R&D facilities in Vadodara.
- To meet general corporate purposes.
Tatva Chintan Pharma LTD IPO – Financial Statements
| Particulars | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 |
| Total Assets | 3,148.03 | 2,489.38 | 1,875.08 |
| Total Revenue | 3,062.92 | 2,646.22 | 2,068.01 |
| Profit After Tax | 522.62 | 377.89 | 205.43 |
Tatva Chintan Pharma LTD IPO Strengths
- Leading manufacturer of structure-directing agents and phase transfer catalysts.
- Diversified product portfolio.
- Global market presence with a customer base across industries.
- Strategically located manufacturing facility in Gujarat with proximity to Hazira Port.
- Experienced promoters and team managers.
- Strong financial performance track record.
Tatva Chintan Pharma LTD IPO Weakness
- Failure to comply with the quality standards and technical specifications prescribed by its institutional customer.
- Dependency on a limited number of supplies for certain raw materials.
Company Contact Information
Tatva Chintan Pharma Chem Ltd
Plot No. 502 / 17, GIDC Estate, Ankleshwar,
Bharuch, Gujarat – 393002, India
Phone: +91 75730 46951
Email: cs@tatvachintan.com
Website: http://www.tatvachintan.com/
Tatva Chintan Pharma IPO Registrar
Phone: +91-22-4918 6270
Email: tatva.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Tatva Chintan Pharma IPO Lead Manager(s)
- ICICI Securities Limited (Past IPO Performance)
- JM Financial Limited (Past IPO Performance)
